Journal of Immunotherapy and Precision Oncology最新文献

{"title":"<i>ESR1</i>-Guided Endocrine Switching in HR-Positive Metastatic Breast Cancer: From Detection to Risk-Adapted Decision in SERENA-6.","authors":"Atlal Abusanad","doi":"10.36401/JIPO-26-5","DOIUrl":"10.36401/JIPO-26-5","url":null,"abstract":"","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"9 3","pages":"120-123"},"PeriodicalIF":3.1,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13403490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148604038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Germline BRCA Status on Pathologic Complete Response (pCR) and Outcomes in Early TNBC Treated with Pembrolizumab-Based Neoadjuvant Chemotherapy (KEYNOTE-522 Regimen): A Real-World Study.","authors":"Mohammad Aldawoud, Fatima Faqihi, Najd Algazlan, Marwa Alharbi, Abdullah Almazyad, Abdulaziz Altamimi, Mojahed Rudaini, Abdullah Alwohaibi, Besher Alghazi, Abdulrahman Alturki, Hatoon Bakhribah, Abdullah Altwairgi","doi":"10.36401/JIPO-26-11","DOIUrl":"10.36401/JIPO-26-11","url":null,"abstract":"<p><strong>Introduction: </strong>Pembrolizumab-based neoadjuvant chemoimmunotherapy following the KEYNOTE-522 regimen (NCT03036488) is a standard treatment approach for stage II and III triple-negative breast cancer (TNBC). Real-world evidence on the impact of germline BRCA status on pathologic complete response (pCR) and survival outcomes remains limited.</p><p><strong>Methods: </strong>We performed a retrospective single-center cohort study of patients with stage II-III TNBC treated with a KEYNOTE-522 regimen between January 2021 and December 2023. Only patients with documented germline BRCA status were included. The primary end point was pCR rate, defined as achievement of ypT0/is ypN0. Secondary end points included treatment delivery (completion and early discontinuation), postneoadjuvant systemic therapy patterns, recurrence-free survival (RFS), and overall survival (OS). Categorical variables were compared using Fisher's exact test, and survival outcomes were estimated using Kaplan-Meier methods and compared with log-rank tests.</p><p><strong>Results: </strong>Among 1004 patients with breast cancer screened between 2021 and 2023, 125 had TNBC. After exclusion of patients who did not receive a KEYNOTE-522 regimen, had metastatic disease, underwent definitive surgery before neoadjuvant systemic therapy, had unretrievable BRCA status, or had other missing key eligibility data, 54 patients were eligible for analysis. The final cohort included 11 patients who were BRCA+ and 43 who were BRCA-. The BRCA+ patients were younger than BRCA- patients (median 38 vs 46 years; <i>p</i> = 0.018). pCR was evaluable in 52 patients and was achieved in 31 of 52 patients (60%) overall; pCR was numerically higher in BRCA+ vs BRCA- patients (73% [8 of 11] vs 56% [23 of 41]; <i>p</i> = 0.49). Median follow-up was 25 months. Two-year RFS was 100% in BRCA+ and 75.4% in BRCA- patients (log-rank <i>p</i> = 0.068), whereas 2-year OS was 100% and 88%, respectively (log-rank <i>p</i> = 0.272). Within the BRCA+ subgroup, the prognostic significance of pCR could not be assessed because no recurrence or death events were observed during follow-up. Within the BRCA- subgroup, pCR strongly stratified prognosis, with 2-year RFS of 100% in patients achieving pCR vs 45.5% in those without pCR (log-rank <i>p</i> = 0.00004), and 2-year OS of 100% vs 72.7%, respectively (log-rank <i>p</i> = 0.018).</p><p><strong>Conclusions: </strong>Germline <i>BRCA</i> positivity was associated with a numerically higher pCR rate, but differences in pCR and survival by BRCA status were not statistically significant. Given the limited sample size and low event counts, these findings should be considered hypothesis-generating. Recurrence events clustered in BRCA- patients and were driven predominantly by those without pCR, supporting further study of optimized postneoadjuvant escalation strategies for residual BRCA- disease.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"9 3","pages":"113-119"},"PeriodicalIF":3.1,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13403491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148604053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating Complexity in the Precision Oncology Clinic: Pharmacists' Central Role in Drug Selection, Acquisition, and Dosing in a Real-World Clinic.","authors":"Justin Grahl, Roberto Ferrusquia, Megan Mills, Rachel Schneider, Abigail Beachy, Hui-Zi Chen, Razelle Kurzrock","doi":"10.36401/JIPO-26-X4","DOIUrl":"10.36401/JIPO-26-X4","url":null,"abstract":"","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"9 3","pages":"109-112"},"PeriodicalIF":3.1,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13366830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148447507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Double-Edged Role of Social Media in Modern Healthcare: Awareness, Impact, and Misinformation.","authors":"Jibran Ahmed, Atlal Abusanad, Gilberto Morgan","doi":"10.36401/JIPO-26-10","DOIUrl":"10.36401/JIPO-26-10","url":null,"abstract":"<p><p>Social media platforms influence healthcare. Social media engagement creates opportunities for health education, networking, patient empowerment, and public health initiatives. However, misinformation is common and circulates alongside accurate information. Additional concerns with online engagement include patient privacy and issues surrounding health disparities. This review examines the role of social media in the modern healthcare system from both the patient and the healthcare provider perspectives with a focus on oncology care. It explores the issues surrounding social media use among patients and the responsibilities of healthcare professionals, institutions, policymakers, and regulatory authorities in harnessing its benefits while mitigating risks. Although social media is a powerful tool for democratizing health information and fostering community support, its unchecked influence requires careful navigation through evidence-based strategies, digital literacy initiatives, and collaborative approaches between patients, technology platforms, and healthcare stakeholders.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"9 3","pages":"100-106"},"PeriodicalIF":3.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13339679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Visibility: Social Media, Trust, and Responsibility in Oncology.","authors":"Joud Hajjar, Mark A Lewis","doi":"10.36401/JIPO-26-X3","DOIUrl":"10.36401/JIPO-26-X3","url":null,"abstract":"","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"9 3","pages":"107-108"},"PeriodicalIF":3.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13339678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148404919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical Advances, and Future Directions.","authors":"Radiya Almosa, Megan Macalalad Mendoza, Tin-Yun Tang, Bettzy Stephen","doi":"10.36401/JIPO-25-36","DOIUrl":"10.36401/JIPO-25-36","url":null,"abstract":"<p><p>A rapidly advancing class of engineered immunoglobulins, known as bispecific antibodies (bsAbs), that bind two distinct antigens offers new approaches for tumor targeting and immune modulation. BsAbs function as immune cell engagers, immune checkpoint modulators, or signaling pathway inhibitors. They differ in half-life, stability, and tissue penetration depending on whether they exist in crystallizable fragment (Fc)-based or fragment-based formats. Although bsAbs have shown strong efficacy in hematologic malignancies, their translation to solid tumors has been limited by antigen heterogeneity, off-tumor toxicity, and the immunosuppressive tumor microenvironment. Recent clinical advancements have led to eight approved bsAbs for solid tumors, including amivantamab for <i>EGFR</i> (epidermal growth factor receptor) exon 20 insertion-mutated non-small cell lung cancer (NSCLC), tebentafusp for uveal melanoma, cadonilimab for cervical cancer, tarlatamab for small cell lung cancer, ivonescimab for PD-L1 (programmed death-ligand 1)-positive NSCLC, zanidatamab for HER2 (human epidermal growth factor receptor 2)-amplified biliary tract cancer, zenocutuzumab for <i>NRG1</i> (neuregulin 1) fusion-positive tumors, and catumaxomab for malignant ascites. These agents have demonstrated durable clinical benefit with manageable safety profiles. However, class-related toxicities such as cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and on-target off-tumor effects remain important challenges. Advances in Fc silencing, affinity tuning, and tumor-restricted activation have improved therapeutic selectivity and tolerability. Ongoing innovations include bsAb-drug conjugates, proteolysis-targeting chimeras (PROTACs), and multispecific antibody platforms designed to reprogram the tumor microenvironment and enhance immune infiltration. Biomarker-driven patient selection and rational combination strategies are expected to further improve outcomes. As engineering technologies mature, bsAbs are expected to become integral to precision oncology, expanding safe and effective immunotherapy options for patients with solid tumors. This review aims to provide a comprehensive overview of the mechanisms, clinical applications, challenges, and future directions of bsAbs in solid tumors.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"9 3","pages":"88-99"},"PeriodicalIF":3.1,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13325624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SMARCA4-Directed Treatment in Oncology Clinical Trials: A Review.","authors":"Sarah Hendee, Gerald Falchook","doi":"10.36401/JIPO-25-35","DOIUrl":"10.36401/JIPO-25-35","url":null,"abstract":"<p><p>SMARCA4 is an ATPase subunit in the switch/sucrose non-fermentable complex (SWI/SNF), a chromatin-remodeling complex. SMARCA4 provides energy for the SWI/SNF complex to regulate gene expression through chromatin structural rearrangement and transcription regulation. In SMARCA4-deficient cancers, its paralog SMARCA2 is sometimes upregulated and can serve as a pharmacological target. Of the 20-25% of cancers identified to have a mutation in a gene encoding a protein for the SWI/SNF complex, 15% of these alterations include <i>SMARCA4</i> alterations. Therefore, SMARCA4-directed therapies are under investigation in clinical trials and are a promising new strategy for treating patients with a <i>SMARCA4</i>-mutated cancer. Currently, all published clinical trials of SMARCA4-directed therapies are for orally bioavailable small-molecule inhibitors. Clinical trials without results include small-molecule inhibitors, monoclonal antibodies, and a bifunctional MabPair product. The aim of this literature review was to summarize the current SMARCA4-directed therapies in oncology clinical trials.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"9 3","pages":"79-87"},"PeriodicalIF":3.1,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13255103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148251844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer.","authors":"Elias A Castro, Yash C Jani, Mehmet A Bilen","doi":"10.36401/JIPO-25-22","DOIUrl":"10.36401/JIPO-25-22","url":null,"abstract":"<p><p>Prostate cancer is the most common non-cutaneous malignancy affecting men in the United States, with the incidence of metastatic disease rising. Despite modern androgen deprivation therapy (ADT), nearly all cases of metastatic prostate cancer develop castration resistance. Informed by successes in the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment modalities have emerged as part of the armamentarium for metastatic hormone-sensitive prostate cancer (mHSPC). In this review, we detail treatments such as cytotoxic chemotherapy, androgen receptor pathway inhibitors (ARPIs), radiotherapy, radiopharmaceutical therapy, immunotherapy, and poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of mHSPC, synthesizing current evidence and guiding clinical decision-making. With technological advances and insight from molecular studies, we discuss emerging biomarkers as indicators to guide prognostication and therapeutic decisions. As a result of these developments, the treatment landscape for mHSPC is evolving toward a precision oncology paradigm incorporating combined systemic therapies.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"9 2","pages":"62-78"},"PeriodicalIF":3.1,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13200518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148031596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstracts Presented at the 2026 Precision Oncology Saudi Summit: February 12-14, 2026, Madinah, Saudi Arabia.","authors":"","doi":"10.36401/JIPO-26-X2","DOIUrl":"10.36401/JIPO-26-X2","url":null,"abstract":"","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"9 2","pages":"46-61"},"PeriodicalIF":3.1,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13082891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Class II Major Histocompatibility Complex Transactivator (CIITA): A Master MHC-II Regulator Impacting Cancer and Beyond.","authors":"Soon Khai Low, Yu Fujiwara, Daisuke Nishizaki, Shumei Kato, Razelle Kurzrock","doi":"10.36401/JIPO-25-31","DOIUrl":"10.36401/JIPO-25-31","url":null,"abstract":"<p><p>The class II major histocompatibility complex transactivator (CIITA) is a non-DNA-binding master regulator of major histocompatibility complex class II (MHC-II) gene expression, essential for antigen presentation and adaptive immunity. Functioning as a scaffold, CIITA recruits chromatin remodelers and transcription coactivators to form the MHC-II enhanceosome, facilitating transcriptional activation. CIITA expression is tightly regulated through four promoters and is subject to both cytokine-induced and epigenetic control. Dysregulation of CIITA underpins several immune-related disorders. Its deficiency results in bare lymphocyte syndrome, a severe immunodeficiency. Variants in the CIITA gene have been implicated in autoimmune diseases, graft rejection, and immune dysregulation. Chromosomal translocations involving CIITA are among the most common genomic alterations in some B-cell lymphomas. Additionally, pathogens such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), and hepatitis B virus (HBV) exploit CIITA suppression to evade immune surveillance. In oncology, epigenetic silencing of CIITA contributes to MHC-II downregulation and tumor immune evasion. Restoration of CIITA expression enhances tumor immunogenicity, T cell infiltration, and responsiveness to immunotherapy. CIITA also modulates the tumor microenvironment, influences prognosis, and has therapeutic relevance in hematologic and solid tumors. Its multifunctional role positions CIITA as a critical immune regulator and a promising therapeutic target in cancer immunotherapy, antiviral strategies, and immune modulation.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"9 2","pages":"36-45"},"PeriodicalIF":3.1,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13078950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}